October 2, 2026 · Peptide Legal Updates
Adding a vitamin to a compounded GLP-1 formulation does not automatically resolve federal restrictions on copying commercially available drugs. FDA’s September 18, 2026 warning letter to Empower Pharmacy puts a narrower issue in focus: whether prescription records reflect actual, individualized clinical decisions.
What FDA identified
The letter followed an inspection of Empower’s Houston facility from November 3–14, 2025. FDA stated that certain tirzepatide/niacinamide and semaglutide/cyanocobalamin products appeared to be essentially copies of approved drugs. The agency questioned the production volume and described the formulation differences as potentially pretextual.
FDA also identified prescriptions lacking a determination of significant difference and others with identical statements across numerous records. It questioned whether preselected options supplied through technology platforms undermined individualized prescribing. The letter separately addressed production-quality deficiencies.
These are FDA’s stated findings in a warning letter, not a criminal conviction or court judgment. The letter acknowledges earlier company responses and requests corrective action; it does not establish that every compounded GLP-1 prescription is unlawful.
The exception requires a patient-specific difference
Under the section 503A framework, regular or inordinate compounding of products that are essentially copies of commercially available drugs can defeat important statutory exemptions. A relevant exception concerns a change that the prescribing practitioner determines produces a significant difference for an identified individual patient.
FDA’s April 1, 2026 policy clarification expressly discusses semaglutide combined with vitamin B12. Depending on ingredients, strengths, administration route, and documented patient-specific differences, such combinations may still be treated as copies. An additional ingredient is therefore not a universal compliance solution.
The agency’s 2018 guidance on essentially copied products does not require a particular documentation format. It calls for clarity about the relevant change and its significant difference for the patient. A patient’s name and a formulation alone are insufficient; a lower price does not itself supply the required formulation-related difference. This is longstanding guidance, not a new October law.
Review the workflow, not just the wording
As a practical compliance step, pharmacies and prescribing organizations should examine how an order moves from consultation to fulfillment. Who selects the formulation? Who evaluates the individual patient? Does the record explain the clinical reasoning, and can the pharmacy obtain clarification when that reasoning is missing?
Templates can organize information, but a business should assess whether its software encourages genuine judgment or merely offers a convenient justification. Replacing one stock phrase with another will not address an underlying process that never evaluates individual circumstances.
Clinics, wellness centers, medical spas, and chiropractic businesses should review the authority and role of every participating professional. A pharmacy relationship does not answer separate questions about licensure, supervision, ownership, referrals, or advertising. Those issues depend on the jurisdiction and actual services offered.
RUO sellers and influencers should also avoid using this compounding exception as a general endorsement of consumer sales. The discussion concerns a specific statutory framework; it does not turn research-labeled merchandise into an authorized patient treatment.
Build a defensible review process
Retain counsel familiar with FDA and healthcare regulation, with pharmacy expertise where needed, to assess product eligibility, prescribing records, technology contracts, marketing, and quality oversight together. Preserve existing records and document corrections accurately; do not backdate clinical judgments or manufacture explanations after the fact.
Request a compliance review through PeptideLitigation.com. Provide your business model, operating states, formulations, and relevant notices so the review can address the actual workflow.
General information as of October 2, 2026, not legal advice. Reading this article or submitting an inquiry does not create an attorney-client relationship.